Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 9Head & Neck 9Dermatologic 7Breast 4Lymphoid 3CNS 3Myeloid 2Genitourinary 2Gastrointestinal 2Other hematologic neoplasm 1Gynecologic 1

Conditions

Prostatic Neoplasms 5016Carcinoma, Renal Cell 1574Urinary Bladder Neoplasms 1279Kidney Neoplasms 723Breast Neoplasms 642Neoplasms 628Carcinoma, Transitional Cell 487Neoplasm Metastasis 468Carcinoma, Non-Small-Cell Lung 467Melanoma 421Ovarian Neoplasms 399Colorectal Neoplasms 370Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 231Stomach Neoplasms 226Uterine Cervical Neoplasms 223Testicular Neoplasms 215Non-Muscle Invasive Bladder Neoplasms 214Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 187Colonic Neoplasms 167Carcinoma, Hepatocellular 165Esophageal Neoplasms 164Endometrial Neoplasms 164Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 128Neuroblastoma 127Small Cell Lung Carcinoma 125

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Soft Tissue Neoplasms × Genitourinary × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT03159585 2020-01-22

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Zhujiang Hospital

Phase 1 Completed
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Soft Tissue Neoplasms, Stomach Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡